The common rule of thumb is that an ROE above 15% is strong. Among US companies with a market capitalization above $2 billion, the median ROE is 11.7%, the middle half fall between 3.1% and 21.8%, and about 40% clear 15%. For companies above $10 billion the median is 14.9%. About 21% of companies above $2 billion have a negative ROE because they lost money over the last twelve months.
| Industry | Median | Middle 50% |
|---|
| Pharma & biotech | -36.8% | -67.6% – 7.4% |
| Medical devices | 3.4% | -22.1% – 15.7% |
| REITs | 5.2% | 0.6% – 9.9% |
| Software & IT services | 6.5% | -8.9% – 23.9% |
| Telecom & media | 7.1% | -5.7% – 18.1% |
| Food & beverage | 8.3% | 1.6% – 17.2% |
| Utilities | 9.8% | 6.9% – 12.2% |
| Oil & gas | 10.0% | -0.3% – 20.2% |
| Semiconductors & hardware | 10.1% | -3.2% – 21.3% |
| Industrial manufacturing | 10.5% | 2.6% – 18.1% |
| Transportation | 10.8% | 1.8% – 21.6% |
| Banks | 10.9% | 8.7% – 12.9% |
| Insurance | 14.0% | 8.3% – 22.1% |
| Retail | 14.3% | 2.9% – 32.4% |
Banks, insurers, and utilities cluster tightly around 10% to 14% because regulation and capital requirements limit how much they can earn on equity. Retailers and software companies spread much wider, from losses to returns above 25%. Pharmaceutical and biotech medians are negative because many are still developing products.
Check how a high ROE is achieved. Heavy borrowing or large buybacks shrink equity and raise ROE without improving the business, and a company with negative equity can show a meaningless figure. Comparing ROE with ROIC and the debt-to-equity ratio separates operating strength from leverage. Figures are GeminIQ calculations across US companies that file with the SEC, using each company's latest reported period as of September 2026. The middle 50% runs from the 25th to the 75th percentile. The industry table groups companies by SIC code and includes those above $300 million in market capitalization.